Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome a antibodies

Clinical and Experimental Immunology

Volumn 147, Issue 3, 2007, Pages 513-520

  Mathsson, L ^a,c   Ahlin E ^a   Sjowall C ^b   Skogh, T ^b   Ronnelid J ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Complement; Cytokines; Immune complex; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; COLLAGEN ANTIBODY; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 6; PROTEIN ANTIBODY; SJOGREN SYNDROME A ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD ANALYSIS; CELL STIMULATION; CHEMICAL ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SCHOOL CHILD; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; C-REACTIVE PROTEIN; CELLS, CULTURED; CHILD; COMPLEMENT PATHWAY, CLASSICAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 33846811374     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03313.x     Document Type: Article

References (40)

1. Koffler D, Agnello V, Thoburn R, Kunkel HG. Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med 1971; 134:169-79.
2. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002; 4 (Suppl. 3):S279-93.
3. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56:481-90.
4. Hassan AB, Lundberg IE, Isenberg D, Wahren-Herlenius M. Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31:133-9.
5. Reichlin M. Systemic lupus erythematosus. Antibodies to ribonuclear proteins. Rheum Dis Clin North Am 1994; 20:29-43.
6. Mongan AE, Ramdahin S, Warrington RJ. Interleukin-10 response abnormalities in systemic lupus erythematosus. Scand J Immunol 1997; 46:406-12.
7. Cross JT, Benton HP. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res 1999; 48:255-61.
8. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147:117-23.
9. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181:839-44.
10. Aljanadi M, Aldalaan A, Alballa S, Alhumaidi M, Raziuddin S. Interleukin-10 (IL-10): secretion in systemic lupus erythematosus and rheumatoid arthritis - Il-10-dependent Cd4+Cd45ro+ T cell B cell antibody synthesis. J Clin Immunol 1996; 16:198-207.
11. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16:283-8.
12. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998; 10:140-7.
13. Liu TF, Jones BM. Impaired production of IL-12 in system lupus erythematosus. II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine 1998; 10:148-53.
14. Capper ER, Maskill JK, Gordon C, Blakemore AI. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin Exp Immunol 2004; 138:348-56.
15. Hesselink DA, Aarden LA, Swaak AJ. Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. Scand J Rheumatol 2003; 32:151-5.
16. Rodriguez W, Mold C, Kataranovski M, Hutt J, Marnell LL, Du Clos TW. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 2005; 52:642-50.
17. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004; 30:261-77.
18. Sjöwall C, Bengtsson T, Skogh T. CRP and anti-CRP autoantibodies in systemic lupus erythematosus. Curr Rheumatol Rev 2005; 1:81-9.
19. Sjöwall C, Bengtsson AA, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004; 6:R87-94.
20. Rönnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis 2003; 62:37-42.
21. Tejde A, Mathsson L, Ekdahl KN, Nilsson B, Rönnelid J. Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system. Clin Exp Immunol 2004; 137:521-8.
22. Mathsson L, Tejde A, Carlson K et al. Cryoglobulin-induced cytokine production via FcgammaRIIa: inverse effects of complement blockade on the production of TNF-alpha and IL-10. Implications for the growth of malignant B-cell clones. Br J Haematol 2005; 129:830-8.
23. Pontese-Carvalho LC, Lannes-Vieira J, Giovanni de-Simone S, Galvao-Castro B. A protein A-binding, polyethylene glycol precipitation-based immunoradiometric assay. Application to the detection of immune complexes and C3 in human sera and of private antigens in cross- reacting parasite extracts. J Immunol Meth 1986; 89:27-35.
24. Mathsson L, Lampa J, Mullazehi M, Rönnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther 2006; 8:R64.
25. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum 2006; 54:1759-71.
26. Nilsson UR, Nilsson B. Simplified assays of hemolytic activity of the classical and alternative pathways. J Immunol Meth 1984; 72:49-59.
27. S Tang Lui SL Lai KN. Pathogenesis of lupus nephritis; an update. Nephrology (Carlton) 2005; 10:783-9.
28. Bengtsson A Nezlin R Shoenfeld Y Sturfelt G. DNA levels in circulating immune complexes decrease at severe SLE flares-correlation with complement component C1q. J Autoimmun 1999; 13:111-19.
29. Gauthier VJ Mannik M. A small proportion of cationic antibodies in immune complexes is sufficient to mediate their deposition in glomeruli. J Immunol 1990; 145:3348-52.
30. Suenaga R Abdou NI. Cationic and high affinity serum IgG anti-dsDNA antibodies in active lupus nephritis. Clin Exp Immunol 1993; 94:418-22.
31. Båve U Nordmark G Lövgren T Rönnelid J Cajander S Eloranta ML Alm GV Rönnblom L. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52:1185-95.
32. Nordmark G Rorsman F Rönnblom L et al. Autoantibodies to alpha-fodrin in primary Sjogren's syndrome and SLE detected by an in vitro transcription and translation assay. Clin Exp Rheumatol 2003; 21:49-56.
33. Salonen EM, Miettinen A, Walle TK, Koskenmies S, Kere J, Julkunen H. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases. Ann Rheum Dis 2004; 63:1250-4.
34. Stanilova SA, Slavov ES. Comparative study of circulating immune complexes quantity detection by three assays - CIF-ELISA, C1q-ELISA and anti-C3 ELISA. J Immunol Meth 2001; 253:13-21.
35. Robinson MW, Scott DG, Bacon PA, Walton KW, Coppock JS, Scott DL. What proteins are present in polyethylene glycol precipitates from rheumatic sera? Ann Rheum Dis 1989; 48:496-501.
36. Crowley-Nowick PA, Campbell E, Schrohenloher RE, Mestecky J, Jackson S. Polyethylene glycol precipitates of serum contain a large proportion of uncomplexed immunoglobulins and C3. Immunol Invest 1996; 25:91-101.
37. Sjöwall C, Eriksson P, Almer S, Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 2002; 19:155-60.
38. Maire MA, Barnet M, Carpentier N, Miescher PA, Lambert PH. Identification of components of IC purified from human sera. I. Immune complexes purified from sera of patients with SLE. Clin Exp Immunol 1983; 51:215-24.
39. Horwitz DA, Gray JD, Behrendsen SC et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998; 41:838-44.
40. Liu TF, Jones BM, Wong RW, Srivastava G. Impaired production of IL-12 in systemic lupus erythematosus. III. deficient IL-12 p40 gene expression and cross-regulation of IL-12, IL-10 and IFN-gamma gene expression. Cytokine 1999; 11:805-11.